Orexo AB (publ) (ORX.ST) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. ORX.ST files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 109.15% | 30.00% | Fail |
| Interest-bearing investments | 199.22% | 30.00% | Fail |
| Non-permissible income | 15.77% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 38.37% | 33.00% | Fail |
| Interest-bearing investments | 70.03% | 33.00% | Fail |
| Non-liquid assets | 15.79% | at least 20.00% | Fail |
| Non-permissible income | 15.77% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 38.37% | 33.33% | Fail |
| Cash + interest-bearing securities | 70.03% | 33.33% | Fail |
| Accounts receivable | 84.21% | 33.33% | Fail |
| Non-permissible income | 15.77% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 38.37% | 33.33% | Fail |
| Cash + interest-bearing securities | 70.03% | 33.33% | Fail |
| Accounts receivable | 84.21% | 50.00% | Fail |
| Non-permissible income | 15.77% | 5.00% | Fail |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 72.01% | 33.00% | Fail |
| Cash + interest-bearing securities | 131.43% | 33.00% | Fail |
| Accounts receivable | 26.61% | 33.00% | Pass |
| Non-permissible income | 15.77% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 76.50% | 33.00% | Fail |
| Cash + interest-bearing securities | 139.62% | 49.00% | Fail |
| Accounts receivable | 28.26% | 49.00% | Pass |
| Non-permissible income | 15.77% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 76.50% | 33.33% | Fail |
| Cash + interest-bearing securities | 139.62% | 33.33% | Fail |
| Accounts receivable | 167.89% | 49.00% | Fail |
| Non-permissible income | 15.77% | 5.00% | Fail |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 39.10 | NEUTRAL |
| Stochastic %K (14) | 13.51 | BUY |
| CCI (20) | -80.22 | NEUTRAL |
| Williams %R (14) | -86.49 | BUY |
| MACD (12,26,9) | 0.07 | BUY |
| ROC (10) | 1.06 | BUY |
| Momentum (10) | 0.14 | BUY |
| EMA (10) | 14.17 | SELL |
| SMA (10) | 14.35 | SELL |
| EMA (20) | 14.49 | SELL |
| SMA (20) | 14.37 | SELL |
| EMA (30) | 14.98 | SELL |
| SMA (30) | 14.48 | SELL |
| EMA (50) | 16.05 | SELL |
| SMA (50) | 16.48 | SELL |
| EMA (100) | 18.27 | SELL |
| SMA (100) | 18.39 | SELL |
| EMA (200) | 22.19 | SELL |
| SMA (200) | 22.40 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.